Ana Martinez-Naharro

List of Publications by Year
in descending order

43 papers	2,809 citations	304743 22 h-index	315739 38 g-index
43 all docs	43 docs citations	43 times ranked	2200 citing authors

#	Article	IF	Citations
1	Distinct cardiovascular phenotypes are associated with prognosis in systemic sclerosis: a cardiovascular magnetic resonance study. European Heart Journal Cardiovascular Imaging, 2023, 24, 463-471.	1.2	7
2	Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. Heart, 2022, 108, 474-478.	2.9	8
3	Clinical Importance of Left Atrial Infiltration in Cardiac TransthyretinÂAmyloidosis. JACC: Cardiovascular Imaging, 2022, 15, 17-29.	5.3	67
4	Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. European Heart Journal, 2022, 43, 333-341.	2.2	45
5	Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. European Heart Journal, 2022, 43, 2622-2632.	2.2	27
6	Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. JACC: Cardiovascular Imaging, 2021, 14, 189-199.	5.3	113
7	Quantitative cardiovascular magnetic resonance myocardial perfusion mapping to assess hyperaemic response to adenosine stress. European Heart Journal Cardiovascular Imaging, 2021, 22, 273-281.	1.2	15
8	Urinary retinol binding protein predicts renal outcome in systemic immunoglobulin lightâ€chain (AL) amyloidosis. British Journal of Haematology, 2021, 194, 1016-1023.	2.5	3
9	Noncontrast Magnetic Resonance for theÂDiagnosis of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 69-80.	5.3	125
10	Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. ESC Heart Failure, 2020, 7, 3942-3949.	3.1	22
11	Diffusion Tensor Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 2020, 13, e009901.	2.6	26
12	The value of screening biopsies in lightâ€chain (AL) and transthyretin (ATTR) amyloidosis. European Journal of Haematology, 2020, 105, 352-356.	2.2	10
13	Diagnostic imaging of cardiac amyloidosis. Nature Reviews Cardiology, 2020, 17, 413-426.	13.7	84
14	Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. European Heart Journal, 2020, 41, 1439-1447.	2.2	108
15	Assessment of Multivessel Coronary Artery Disease Using Cardiovascular Magnetic Resonance Pixelwise Quantitative Perfusion Mapping. JACC: Cardiovascular Imaging, 2020, 13, 2546-2557.	5.3	30
16	Detailed Understating of CardiacÂAmyloidosis by CMR. JACC: Cardiovascular Imaging, 2020, 13, 1311-1313.	5.3	1
17	Atrial Involvement in Cardiac Amyloidosis. JACC: CardioOncology, 2020, 2, 732-734.	4.0	3
18	The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis. Blood, 2020, 136, 40-40.	1.4	1

#	Article	IF	Citations
19	Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities. Journal of the American Heart Association, 2019, 8, e012097.	3.7	21
20	Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation, 2019, 140, 16-26.	1.6	288
21	High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis. Journal of the American College of Cardiology, 2019, 73, 1733-1734.	2.8	65
22	Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance. Scientific Reports, 2019, 9, 1388.	3.3	27
23	Automated Pixel-Wise Quantitative Myocardial Perfusion Mapping by CMRÂtoÂDetect Obstructive Coronary Artery Disease and Coronary Microvascular Dysfunction. JACC: Cardiovascular Imaging, 2019, 12, 1958-1969.	5.3	140
24	19â€...Myocardial perfusion mapping in cardiac amyloidosis- unearthing the spectrum from infiltration to ischaemia. , 2019, , .		0
25	Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience. Human Mutation, 2019, 40, 90-96.	2.5	29
26	Native T1 and Extracellular Volume inÂTransthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2019, 12, 810-819.	5.3	172
27	Cardiac Structural and Functional Consequences of Amyloid Deposition byÂCardiac Magnetic Resonance andÂEchocardiography and TheirÂPrognosticÂRoles. JACC: Cardiovascular Imaging, 2019, 12, 823-833.	5.3	113
28	Cardiac amyloidosis. Clinical Medicine, 2018, 18, s30-s35.	1.9	135
29	CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy. JACC: Cardiovascular Imaging, 2018, 11, 152-154.	5.3	90
30	A new staging system for cardiac transthyretin amyloidosis. European Heart Journal, 2018, 39, 2799-2806.	2.2	396
31	Extracellular volume with bolusâ€only technique in amyloidosis patients: Diagnostic accuracy, correlation with other clinical cardiac measures, and ability to track changes in amyloid load over time. Journal of Magnetic Resonance Imaging, 2018, 47, 1677-1684.	3.4	7
32	3â€...Treatment response in cardiac al amyloidosis assessed by CMR: findings at 3 months, 6 months and 1 year post-chemotherapy. , 2018, , .		0
33	Reply. Journal of the American College of Cardiology, 2018, 72, 1881.	2.8	2
34	Myocardial Edema and Prognosis inÂAmyloidosis. Journal of the American College of Cardiology, 2018, 71, 2919-2931.	2.8	145
35	Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. European Heart Journal Cardiovascular Imaging, 2017, 18, 1344-1350.	1.2	124
36	Magnetic Resonance in TransthyretinÂCardiac Amyloidosis. Journal of the American College of Cardiology, 2017, 70, 466-477.	2.8	290

#	Article	IF	Citations
37	001â€...Multiparametric mapping to understand pathophysiology in cardiac amyloidosis. Heart, 2017, 103, A1-A2.	2.9	12
38	024â€...Spectrum and significance of CMR findings in cardiac transthyretin amyloidosis. Heart, 2017, 103, A20-A21.	2.9	0
39	028â€...Routine identification of hypoperfusion in cardiac amyloidosis by myocardial blood flow mapping. Heart, 2017, 103, A24-A24.	2.9	3
40	008â€...Demonstration of cardiac AL amyloidosis regression after succesful chemotherapy. a CMR study. Heart, 2017, 103, A7.1-A7.	2.9	0
41	A case report in cardiovascular magnetic resonance: the contrast agent matters in amyloid. BMC Medical Imaging, 2017, 17, 3.	2.7	9
42	Staging Cardiac Amyloidosis With CMR. JACC: Cardiovascular Imaging, 2016, 9, 1278-1279.	5.3	10
43	Prospective comparison of novel dark blood late gadolinium enhancement with conventional bright blood imaging for the detection of scar. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 91.	3.3	36